Resmetirom

Resmetirom is a thyroid hormone receptor-beta (THR-beta) agonist. On March 14, 2024, it was approved by the FDA as the first treatment of liver fibrosis due to noncirrhotic non-alcoholic steatohepatitis (NASH), that is a form of non-alcoholic fatty liver disease (NAFLD). Thyroid hormones directly regulate lipid metabolism in the liver; thus, impaired thyroid function, including low serum thyroid hormone levels, is often observed in NAFLD. Resmetirom works to reduce liver fat by stimulating fatty acid degradation and oxidation. It is grouped under the following drug class(es): Thyroid agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include VIA-3196, Rezdiffra and resmetiromum. Its PubChem CID is 15981237.

CAS No 920509-32-6
Molecular Formula C17H12Cl2N6O4
Molecular Weight 435.2 g/mol
Synonyms 2-[3,5-dichloro-4-[(6-oxo-5-propan-2-yl-1H-pyridazin-3-yl)oxy]phenyl]-3,5-dioxo-1,2,4-triazine-6-carbonitrile

Frequently Asked Questions